Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system
about
Abnormalities of angiotensin regulation in postural tachycardia syndromeNew perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failureEffects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure ratsCirculating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiologyACE2 improves right ventricular function in a pressure overload model.Effects of ACE2 inhibition in the post-myocardial infarction heart.The past, present and future of renin-angiotensin aldosterone system inhibitionRole of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study.Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitusACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injuryTargeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failureEvaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review.ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy.Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit.Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease.ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapyα-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17.Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart FailureReduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure.B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity.Pathological Ace2-to-Ace enzyme switch in the stressed heart is transcriptionally controlled by the endothelial Brg1-FoxM1 complex.Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse.Angiotensin-converting enzyme 2 as a therapeutic target for heart failureNovel neurohormonal insights with therapeutic potential in chronic heart failure.ACE2, a promising therapeutic target for pulmonary hypertension.The ACE2 gene: its potential as a functional candidate for cardiovascular disease.Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases.Emerging biomarkers for heart failure: an update.Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis.Future drug discovery in renin-angiotensin-aldosterone system intervention.Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension.Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization.Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation.
P2860
Q24606817-07002402-A36D-4C95-9C68-D8E1EA67D621Q28541744-4EC46CAC-A9DA-4242-B4A6-31B8D6956BF8Q33654750-2BA2488A-3B35-42D2-A98F-C8C8CEA7EF65Q33748856-0C539E79-3615-4F5C-80F7-F0656C3E9F87Q33939495-58D5F865-2C3C-4B15-81E4-62C5F6577C6AQ34088930-8FBA5A74-116D-4DA1-B63F-E688FC6A229FQ34094354-2CA87DE1-7394-40E2-BDAA-0966084DF203Q34695637-FE71D1DC-BA15-4CF1-A6C2-DF8A02FD6D38Q34729883-6F69A1A9-96E2-4C3B-81C6-D8D7F879D1D1Q34866649-0D856687-7F82-43BD-B756-57E24B7650D9Q34892110-455C1417-A505-4C6A-9D0B-8DB5E13E51ADQ34992879-7C491122-FB21-41AC-BEB6-1BDC3071AC7BQ35138448-200CA11D-1507-4471-9F10-174E7E594BD0Q35148756-990867BB-CE60-4FB4-B1FC-174AFE3664CDQ35152116-2BD85873-9883-4DE3-87A5-07DE80BBDBE6Q35229766-DAAEF5F6-8B3F-4198-91C4-706CA7B2C4BCQ35588005-F54A12E7-0762-4F8C-9412-92517FC54601Q35760437-008BDBE1-257C-4EC1-9CAE-45EA42E78B3BQ36114331-3C0CB665-2453-45A7-AFF5-F2B01B1413A9Q37081415-8E268723-908B-4D0A-AA7E-CC4FE04A44C4Q37162741-7CCE0AAA-B9C3-4310-B324-3F060981D8D0Q37194713-C033FCC0-221C-43E1-BBFF-233E8EC5E080Q37217952-FED61440-3AE3-4300-9DDC-50B6412664F7Q37281630-23A51B0F-ED4C-4A92-9329-54AF2500B8FDQ37439317-6D7B9E30-C25F-45BB-BAB0-D164AC70E271Q37620934-3F6B8B26-1C52-4F29-8E3A-5ACE354811FAQ37749836-27FAB581-D180-4DAF-A746-377E43E890B7Q37826865-3F144735-03CF-4659-B40C-190C147EAAD5Q38046618-547FF190-9DB1-4A3F-BFA3-2BEFC9D9FAE7Q38083745-C3D3517E-174E-4B85-8FA0-856C1EA45556Q38170474-669C44D0-BC2D-4967-8F1B-D2FF33D3E42AQ38207841-E5466DFD-E4F8-4F09-9151-A73239CC5F42Q38214892-02E50BDE-D95C-4ED2-9163-DCACA4322990Q38249995-8B183BCF-F168-4E7E-ACD3-02D100DA62B2Q38317550-48FDE3AC-5059-43F0-BE57-1DA77460BDE7Q38679303-470B8802-3344-472E-A81A-6126CEB3C0E5Q38781945-862E5DD4-3AA5-46BC-B852-F3BBFE768F5BQ39599579-7D38CDD5-B85E-4790-BF6E-603EA0440616Q41943681-395F942E-B095-4ECE-B5D3-B2B8FB2447BEQ42663141-192764C7-7FCC-4183-AE10-3DFD167BEBFB
P2860
Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Detection of soluble angiotens ...... angiotensin-aldosterone system
@ast
Detection of soluble angiotens ...... angiotensin-aldosterone system
@en
type
label
Detection of soluble angiotens ...... angiotensin-aldosterone system
@ast
Detection of soluble angiotens ...... angiotensin-aldosterone system
@en
prefLabel
Detection of soluble angiotens ...... angiotensin-aldosterone system
@ast
Detection of soluble angiotens ...... angiotensin-aldosterone system
@en
P2093
P2860
P1476
Detection of soluble angiotens ...... angiotensin-aldosterone system
@en
P2093
Frederick Van Lente
Gary S Francis
Slava Epelman
Stephen Y Chen
W H Wilson Tang
P2860
P304
P356
10.1016/J.JACC.2008.02.088
P407
P577
2008-08-01T00:00:00Z